Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SELECTor: Toripalimab Consolidation in Unresectable Locally Advanced ESCC
NCT07246330Phase 3Recruiting
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Mar 2026
- Primary completion
- Dec 2027
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of toripalimab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Tianjin Medical University Cancer Institute and Hospital. Started Mar 2026; status: recruiting.
02
Drugs
toripalimab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT07246330.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07246330.